Honest answer: most users feel nothing. Selenium is a nutrient-correction intervention, not a pharmacology — if you're already at adequate status (which most US adults are), the proteins are saturated and additional selenium has no acute behavioral or perceptual effect. The dopamine.club community-data block reflects this: top "effects" are vague wellness-adjacent labels (energy, sleep-quality, focus, mood) at modest counts (35-80 mentions each across 583 reports), and the side-effect labels match — same vague wellness vocabulary. This is the pattern you see for any nutrient where most reporters are already replete.

Users who do report effect tend to fall into one of four buckets:

1. Hashimoto's / autoimmune thyroid patients — weeks-to-months of selenomethionine 200 mcg/day correlates with reduced "thyroid fatigue," mood improvement, and (objectively) TPO-Ab decline. The subjective effect maps to the antibody change — slow, cumulative, not a "felt dose."
2. Confirmed-deficient individuals (selenium-poor diet, malabsorption, region-specific) — meaningful symptomatic improvement on correction. Rare in well-fed populations.
3. Hyperthyroid / Graves' patients — anecdotal "stabilization" of palpitations + anxiety on selenium adjunct, consistent with the Marcocci data on orbitopathy + general antioxidant support.
4. Hypochondriacs / placebo-responders — vague reports of better immunity, less fatigue, etc., overlapping with the same crowd that swears by multivitamins.

At supplemental doses (100-200 mcg/day): No acute psychotropic effect. No alertness or sedation. No GI effect at therapeutic doses. If you "feel something" within hours of a selenium capsule, that's almost certainly the rest of the formulation (e.g., iodine in thyroid blends) or placebo.

At toxic doses (>900 mcg/day chronically): Onset of selenosis over weeks — garlic-odor breath, brittle nails (especially horizontal white bands), hair shedding, fatigue, irritability, rarely peripheral neuropathy or hepatic dysfunction. Reversible with discontinuation but takes months given the long half-life.

• No pharmacological tolerance. Selenium is a nutrient — once selenoproteins are saturated (~60-70 mcg/day intake), the relationship between further intake and physiological effect is flat to negative. There is no upregulation/downregulation of selenium-handling proteins that produces "drug tolerance."
• Body pool saturates over 3-6 months of consistent intake (long whole-body half-life). Steady-state serum selenium reflects intake from ~3 months prior.
• Cycling not needed for nutrient-replacement use. No benefit to deliberate "selenium holidays."
• Re-evaluation cadence: Annual serum selenium check if chronically dosing ≥200 mcg/day. Discontinue or reduce if serum >150 mcg/L (top end of population reference range; selenoprotein saturation already maximal).
• Discontinuation: No withdrawal. Body selenium pool depletes over months; serum levels return toward baseline over 6-12 months depending on diet.

Synergistic / complementary

• Iodine. Co-cofactor for thyroid hormone synthesis (iodine builds T4, selenium activates T4→T3). The two together are the canonical "thyroid support" pairing. Caution: iodine excess + selenium deficiency can worsen Hashimoto's (iodine drives autoimmunity via thyroglobulin iodination); the safe pairing is "adequate but not excessive" of both — iodine ≤150-300 mcg/day, selenium ≤200 mcg/day. The dopamine.club community-data block shows iodine as #8 most-co-supplemented compound (147 co-mentions), consistent with this pairing.
• Vitamin E. Both are membrane antioxidants — selenium-dependent GPx4 reduces lipid peroxides that vitamin E (α-tocopherol) helps prevent forming. Mild biochemical synergy; the SELECT trial co-administered them but didn't see additive clinical benefit. Not a meaningful synergy in practice for healthy adults.
• Zinc + selenium (dopamine.club's #1 stacking partner, 317 co-mentions). Both trace minerals, both essential, both immune-relevant. No specific pharmacological synergy beyond "general micronutrient adequacy." Reasonable to co-supplement at RDA-ish doses if intake is uncertain.
• NAC / glutathione precursors (#6, 154 co-mentions). GPx requires reduced glutathione as substrate — selenium without adequate GSH is a partial implementation. NAC provides cysteine for GSH synthesis. Theoretically supports the antioxidant network; not RCT-tested.
• Copper. Selenoprotein P binds copper; selenium and copper homeostasis are interlinked. Most adults are copper-replete. The dopamine.club #7 partner (copper, 153 co-mentions) likely reflects thyroid/mineral-stack culture, not specific synergy.

Avoid stacking with

• High-dose vitamin C at same time as selenite/selenate (reduces selenium to unabsorbable form). Selenomethionine unaffected. Workaround: separate by ≥2 hours, or use selenomethionine form.
• Statin / chemotherapy contexts: Selenium can interfere with chemo-induced ROS-mediated cytotoxicity (theoretical concern); discuss with oncologist. Some selenium chemotherapy-co-administration trials show benefit, others harm.
• Anticoagulants: Mild theoretical antiplatelet effect at high doses; clinically minor at therapeutic intakes.

Neutral / safe co-administration

• Multivitamins, magnesium, vitamin D, omega-3, B-complex — all safe and routine co-administration. No PK interactions of note.
• Caffeine, L-theanine, creatine, ashwagandha — no interactions.
• Modafinil (Dylan's primary stim) — no interactions, no theoretical concern.

• No relevant CYP interactions. Selenium is not metabolized by hepatic CYPs in any clinically meaningful way; it's incorporated into proteins via dedicated selenocysteine machinery.
• Levothyroxine / thyroid medications: No direct PK interaction. Selenium may improve T4→T3 conversion efficiency over months, potentially altering levothyroxine dosing requirements modestly in some patients — clinical monitoring (TSH, fT4) standard during the first 3-6 months of selenium initiation in patients on thyroid replacement.
• Antithyroid drugs (methimazole, PTU): No PK interaction; selenium has been studied as adjunctive therapy in Graves' (positive signal — Marcocci 2011).
• Cisplatin / platinum chemotherapy: Selenium may reduce nephrotoxicity (animal data); not robust clinical evidence; oncology decision.
• Warfarin / anticoagulants: Mild antiplatelet effect of selenium not clinically significant at therapeutic doses; no INR effect expected.
• Contraceptive interactions: None known.
• Renal impairment: Selenium accumulates with reduced GFR; consider dose reduction (50%) or discontinuation in CKD stage 3+.
• Liver disease: Generally safe at RDA-range doses; SELENOP synthesis declines in advanced liver disease (cirrhosis can cause functional selenium deficiency despite adequate intake).

Selenium pharmacogenomics is an emerging but not yet clinically actionable field. Several SNPs affect selenoprotein expression and selenium handling — relevant for research, mostly not for individual decisions in 2026.

• SELENOP (rs7579) / SELENOP haplotypes: Affect plasma selenoprotein P concentration; some haplotypes associated with altered selenium requirements. Not actionable.
• GPX1 (rs1050450, P198L): L-allele reduces GPx1 activity; modestly associated with cancer risk in some cohorts. Theoretical relevance for cancer-prevention use case — but SELECT and Cochrane data already say "don't supplement for cancer prevention" regardless of genotype, so this is moot.
• GPX4 (rs713041): Affects expression; relevant to ferroptosis susceptibility. Research-tier only.
• DIO2 (rs225014, Thr92Ala): Reduces deiodinase activity; some studies suggest Ala/Ala carriers benefit more from T3/T4 combination therapy or selenium support. Not yet actionable in 2026 guidelines.
• SBP2 (SECISBP2 / SBP2): Rare loss-of-function mutations cause functional selenoprotein deficiency syndromes — clinically distinctive (growth delay, infertility, abnormal thyroid hormone metabolism). Treated with selenium + thyroid management.

Practical takeaway for Dylan (23andMe results due June 2026): Selenium pharmacogenomics will not meaningfully change the verdict. The "supplement if low-status, don't if replete" rule is genotype-robust. Even if Dylan's 23andMe shows a GPX1 P198L variant, the clinical decision stays the same — measure status, supplement modestly if needed, don't chase high doses.

Sourcing-difficulty rating: Easy. Selenium is FDA GRAS, widely available OTC at any pharmacy, supplement store, or grocery. No prescription, no gray market, no import concerns.

Recommended Dylan protocol: 1 Brazil nut/day from a fresh bag, OR 100 mcg selenomethionine capsule (Pure Encapsulations or Thorne) from iHerb/Amazon. Total cost: $0.10-0.20/day either way.

Pre-supplementation (baseline):

• Serum or plasma selenium — target range 80-150 mcg/L (reference: ~70-150 in US adults). Below 80 = consider supplementation; above 150 = do not supplement.
• TSH, fT4, fT3 — thyroid panel before and 3 months into supplementation (especially if Hashimoto's use case or already on thyroid replacement).
• TPO antibodies, TgAb — if Hashimoto's use case or family history of autoimmune thyroid disease. Baseline and at 3-6-12 months.
• HbA1c, fasting glucose — if any T2D risk factors (family history, BMI, lipids). Avoid chronic high-dose supplementation if prediabetic.

During supplementation:

• Serum selenium at 3-6 months — confirm not exceeding 150 mcg/L.
• TPO-Ab quarterly (Hashimoto's use case) — primary outcome.
• Nail / breath / hair self-check monthly — selenosis early warning.
• HbA1c annually if chronic ≥200 mcg/day.

Post-discontinuation:

• Serum selenium normalizes over 6-12 months; no specific monitoring needed unless selenosis was present.

Dylan-specific: When June 2026 bloodwork lands, ask for serum selenium addition to the panel (often included in trace-mineral panels; otherwise ~$30 add-on). If <100 mcg/L → 1 Brazil nut/day or 100 mcg capsule. If 100-150 → no supplementation needed. If >150 → no supplementation, reduce Brazil-nut frequency if any.